Loratadine
Loratadine or Claritin is H1 receptor antagonist which is commonly used as a non-sedating anti-histamine.[1][2][3] It is a potential treatment for mast cell activation syndrome (MCAS).[1][2] Loratadine is sometimes misspelled as Loratidine.[2]
Theory[edit | edit source]
Evidence[edit | edit source]
MCAS and ME/CFS[edit | edit source]
The March 2 and 3, 2018, physicians summit in Salt Lake City, Utah addressed the potential role of MCAS treatment in ME/CFS treatment.[1] Several physicians remarked on the relatively high prevalence of MCAS in their ME/CFS patients (making estimating of roughly half their patients) and its significance in pointing toward treatment of symptoms associated with ME/CFS. Dr. Susan Levine suggested that while MCAS likely only affects a subset of ME/CFS patients, for those it does, it can manifest as inability to tolerate certain foods or medications and "If we can reduce the mast cell problem, we can facilitate taking other drugs to treat ME/CFS."[1]
Long COVID[edit | edit source]
Loratadine has limited evidence for use in Long COVID patients from a small observational study by Glynne et al. (2022).[4]
Side effects[edit | edit source]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
- 2022, Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines[4] - (Full text)
Learn more[edit | edit source]
- Medications to Treat Mast Cell Diseases - The Mast Cell Disease Society
- Loratadine - drugs.com
See also[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 1.2 1.3 Tucker, Miriam E. (March 13, 2018). "Mast Cell Activation May Underlie 'Chronic Fatigue Syndrome'". Medscape. Retrieved July 30, 2019.
- ↑ 2.0 2.1 2.2 "Medications to Treat Mast Cell Diseases". The Mast Cell Disease Society. Retrieved February 16, 2021.
- ↑ "Loratadine". drugs.com. Retrieved February 17, 2021.
- ↑ 4.0 4.1 Glynne, Paul; Tahmasebi, Natasha; Gant, Vanya; Gupta, Rajeev (January 2022). "Long COVID following mild SARS-CoV-2 infection: characteristic T cell alterations and response to antihistamines". Journal of Investigative Medicine. 70 (1): 61–67. doi:10.1136/jim-2021-002051. ISSN 1081-5589. PMC 8494538. PMID 34611034.
